Detailed studies on the mechanisms of immune checkpoints have shown that ICIs such as CTLA-4 and PD-1/PD-L1 exhibit effective anti-tumor activity in malignancies such as urothelial carcinoma, renal cell carcinoma, Hodgkin lymphoma, non-small-cell lung cancer, and melanoma. Here, CTLA4 is linked to neoplasm.